◆英語タイトル:Keio University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9324
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Keio University (Keio) is an educational institution that offers education and research services. The institute provides primary and secondary education, graduate and undergraduate courses, and information technology courses. It offers academic courses in the fields of law and economics, humanities and social science, political science, environment and information studies, policy management, business and commerce, medicine, theology and religious studies, history and archaeology, nursing and pharmaceutical sciences, and communication and media studies, among others. The institute operates through its campuses located in Mita, Hiyoshi, Yagami, Shinanomachi, Tonomachi, Tsuruoka, and others. Keio is headquartered in Tokyo, Japan.
Keio University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Keio University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Keio University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Keio University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Keio University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Keio University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Keio University, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Eisai Enters into Agreement with Keio University 10
Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 11
R-Tech Ueno Enters Into Co-Development Agreement With Keio University School Of Medicine 12
Licensing Agreements 13
SymBio Pharma Enters into Research Agreement with Keio University 13
JSR Enters into Licensing Agreement with Keio University 14
Elixirgen Enters into License Agreement with Keio University 15
Keio University – Key Competitors 16
Keio University – Key Employees 17
Keio University – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 20
Government and Public Interest 20
Feb 01, 2018: Keio Global Research Institute Research: Analyzing the Impact of Japan’s Regenerative Medicine Regulatory Reforms 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21
List of Tables
Keio University, Pharmaceuticals & Healthcare, Key Facts 2
Keio University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Keio University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Keio University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Keio University, Deals By Therapy Area, 2012 to YTD 2018 8
Keio University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Eisai Enters into Agreement with Keio University 10
Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 11
R-Tech Ueno Enters Into Co-Development Agreement With Keio University School Of Medicine 12
SymBio Pharma Enters into Research Agreement with Keio University 13
JSR Enters into Licensing Agreement with Keio University 14
Elixirgen Enters into License Agreement with Keio University 15
Keio University, Key Competitors 16
Keio University, Key Employees 17
Keio University, Other Locations 18
Keio University, Subsidiaries 18
List of Figures
Keio University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Keio University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Keio University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Keio University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Keio University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Keio University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Keio University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8